Nicotinamide riboside (NR) and healthy aging

What 2 graded rows on nicotinamide riboside (nr) agree on for healthy aging, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Nicotinamide riboside (NR) page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Nicotinamide riboside (NR) page, with its PubMed record.

Supplement

Nicotinamide riboside (NR) Choose another

2 rows · 110 people

They agree: both rows found an improvement.

No difference

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside.

From the rows

The best-graded row, grade C, is a randomized trial of 90 people (2024) and found an improvement.

The rows run from 20 to 90 people, published in 2024: 2 single studies.

2 improved

Grade CSix-minute walking distance · Improved
RCT · n 90 · 2024 · People with lower-extremity peripheral artery disease
Not stated in the abstract · 6 months
NR improved six-minute walk versus placebo (+7.0 vs -10.6 meters; difference +17.6 m). Adding resveratrol did not add benefit.
Row on the Nicotinamide riboside (NR) page · PubMed 38871717 (opens PubMed)
Grade CBlood NAD+ levels · Improved
RCT · n 20 · 2024 · Older adults with mild cognitive impairment
Escalated to 1 g/day · 10 weeks
Blood NAD+ rose 2.6-fold with NR, with no between-group difference in adverse events. Cognition scores (MoCA) did not change.
Row on the Nicotinamide riboside (NR) page · PubMed 37994989 (opens PubMed)